The Cass Review has attracted considerable international criticism from medical professionals and organisations worldwide, primarily due to concerns about its research methodology and the potential impact of its recommendations on transgender healthcare.
International critics highlight several key issues with the review's approach. Medical professionals argue that the review applied inappropriately stringent standards when evaluating existing research, effectively dismissing evidence that other medical bodies consider robust. Many established medical organisations outside the UK maintain that the review's conclusions contradict evidence-based practices that have been successfully implemented in numerous countries. Research from international healthcare systems suggests that the standards of evidence the Cass Review demanded may not align with those typically applied in clinical medicine.
The criticism has intensified as healthcare providers observe the real-world consequences of implementing the review's recommendations. Medical professionals report seeing young transgender people experiencing distressing physical changes that established treatments could have prevented. International medical bodies express concern that these outcomes demonstrate the potential for the review's approach to cause harm rather than improve patient care.
Evidence from healthcare systems in other countries continues to support different approaches to transgender care, creating a significant divergence between UK policy and international medical consensus. This disconnect has prompted ongoing dialogue within the global medical community about best practices for supporting transgender patients, particularly young people navigating their healthcare journey.